AEON Biopharma, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q4 2023

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: AEON Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q4 2023.
AEON Biopharma, Inc. Debt-to-equity for the quarter ending December 31, 2023 was -109 %, a 93.3% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q4 2023	-109	-52.4	-93.3%	Dec 31, 2023
Q3 2023	-71.2	+33.3	+31.9%	Sep 30, 2023
Q2 2023	-55.1	+56.5	+50.6%	Jun 30, 2023
Q1 2023	-55.2	+56.4	+50.5%	Mar 31, 2023
Q4 2022	-56.2	+56.7	+50.2%	Dec 31, 2022
Q3 2022	-104	+10.6	+9.22%	Sep 30, 2022
Q2 2022	-112			Jun 30, 2022
Q1 2022	-112			Mar 31, 2022
Q4 2021	-113			Dec 31, 2021
Q3 2021	-115			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.